Elite in Pyruvate Kinase Deficiency

Dr. Janet L. Kwiatkowski

Pediatric Hematology Oncology
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
29 Years of Experience
Elite in Pyruvate Kinase Deficiency
3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, 
Philadelphia, PA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Janet Kwiatkowski is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Kwiatkowski has been practicing medicine for over 29 years and is rated as an Elite provider by MediFind in the treatment of Pyruvate Kinase Deficiency. Her top areas of expertise are Hemolytic Anemia, Congenital Hemolytic Anemia, Anemia, Splenectomy, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 97 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 8 articles and participated in 1 clinical trial in the study of Pyruvate Kinase Deficiency.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatrics in PA
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Avalon Health Care
  • MEDICARE PDP
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Gateway Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • OTHER MEDICARE PART D
Health Partners Plans
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

3401 Civic Center Blvd, Children's Hospital Of Philadelphia - Hem/onc, Philadelphia, PA 19104

Additional Areas of Focus

Dr. Kwiatkowski has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
A Randomized, Open-label, Multicenter, Two Arm, Phase II Study to Evaluate Treatment Compliance, Efficacy and Safety of an Improved Deferasirox Formulation (Granules) in Pediatric Patients With Iron Overload
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug
Study Drug: Deferasirox
Study Phase: Phase 2
Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children
Hydroxyurea to Prevent Central Nervous System (CNS) Complications of Sickle Cell Disease in Children
Enrollment Status: Completed
Publish Date: July 10, 2024
Intervention Type: Drug
Study Drug: Hydroxyurea
Study Phase: Phase 2
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Safety and Efficacy of Early-start Deferiprone Treatment in Infants and Young Children Newly Diagnosed With Transfusion-dependent Beta Thalassemia
Enrollment Status: Completed
Publish Date: March 15, 2024
Intervention Type: Drug
Study Phase: Phase 4
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
A Phase 1/2, Open-label, Single-arm Study to Assess the Safety, Tolerability, and Efficacy of ST-400 Autologous Hematopoietic Stem Cell Transplant for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)
Enrollment Status: Completed
Publish Date: December 14, 2023
Intervention Type: Genetic
Study Drug: BCL11A-Positive CD34-Positive Hematopoietic Stem Cells
Study Phase: Phase 1/Phase 2
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients With Sickle Cell Disease or Other Anemias
Enrollment Status: Terminated
Publish Date: August 10, 2021
Intervention Type: Drug
Study Phase: Phase 4
Pyruvate Kinase Deficiency (PKD) Natural History Study
Pyruvate Kinase Deficiency (PKD) Natural History Study
Enrollment Status: Completed
Publish Date: May 22, 2020
View 5 Less Clinical Trials

98 Total Publications

Prevalence of Antiplatelet and Anticoagulation Therapy in Children with Sickle Cell Anemia and Stroke.
Prevalence of Antiplatelet and Anticoagulation Therapy in Children with Sickle Cell Anemia and Stroke.
Journal: Pediatric stroke
Published: May 13, 2025
Similar Doctors
Experienced in Pyruvate Kinase Deficiency
Dr. Michele P. Lambert
Pediatric Hematology Oncology
Experienced in Pyruvate Kinase Deficiency
Dr. Michele P. Lambert
Pediatric Hematology Oncology

Childrens Health Care Associates Inc

3401 Civic Ctr Blvd, 
Philadelphia, PA 
 (0.1 miles away)
215-590-1000
Languages Spoken:
English
See accepted insurances

Michele Lambert is a Pediatric Hematologist Oncology provider in Philadelphia, Pennsylvania. Dr. Lambert is rated as a Distinguished provider by MediFind in the treatment of Pyruvate Kinase Deficiency. Her top areas of expertise are Immune Thrombocytopenic Purpura (ITP), Blood Clots, Evans Syndrome, Multisystem Inflammatory Syndrome in Children (MIS-C), and Splenectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kwiatkowski's expertise for a condition
ConditionClose
View All 8 Elite Conditions
    View All 19 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile